Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB, Harvard extend research collaboration
The research agreement includes a collaboration with the laboratory of Junying Yuan,Professor of Cell Biology at Harvard Medical School. The School aims at translating and developing small molecule
The research agreement includes a collaboration with the laboratory of Junying Yuan,Professor of Cell Biology at Harvard Medical School. The School aims at translating and developing small molecule
ZzzQuil, which comes in both liquid (Warming berry-flavour) and a LiquiCap forms, helps relieve occasional sleeplessness through its single active ingredient, diphenhydramine HCI. North America Vicks marketing director
The patent is entitled Methods and Compositions for Administration of TRPV1 Agonists. The patent which covers formulation, system, and kit claims will remain in effect in Japan until
Atherotech leverages BGM Galectin-3 test to offer galectin-3 testing. The BGM Galectin-3 test was cleared as an aid in assessing the prognosis of patients diagnosed with chronic heart
Edluar, which was developed by Orexo using its proprietary sublingual formulation technologies, is indicated for treatment of insomnia characterized by difficulties with sleep initiation. Orexo chief executive officer
The collaboration will apply KineMed’s biomarker discovery platform in therapeutic areas of interest to GSK. KineMed president and CEO David Fineman said, "The marriage of KineMed’s insights into
EIA is used for Quantitative Determination of anti-Angiotensin II Receptor 1 (AT1) Antibodies. The application screens antibodies that form against Angiotensin II Type I Receptors (AT1R). AT1R involves
Perceptive Informatics, PAREXEL’s technology subsidiary, developed the fully-integrated eClinical platform. PAREXEL chief operating officer Mark Goldberg said with the availability of PAREXEL MyTrials, users will have a single
The study’s independent Data Monitoring Committee concluded that the treatment with saridegib was similar to placebo and, hence, the trial would not meet its primary endpoint, the progression-free
Duexis is used for the relief of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers. Mallinckrodt,will promote Duexis to targeted physicians and